English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Nonalcoholic fatty liver disease (NAFLD) is one of the most prevalent liver diseases in industrialized countries, with approximately 30%-40% of adults suffering from NAFLD. Of those, 15%-20% will develop to its progressive entity nonalcoholic steatohepatitis (NASH), a condition that may further progress to liver fibrosis and cirrhosis. Because insulin resistance and visceral obesity are major contributors in the pathogenesis of NAFLD/ NASH, weight loss, exercise, and insulin-sensitizing drugs are considered as primary treatment regimens. Obeticholic acid, a farnesoid X nuclear receptor agonist, previously approved for the treatment for primary biliary cholangitis, is currently in a phase III trial for patients with NASH fibrosis. In the United States, no effective treatments for NAFLD/NASH have been approved by the U.S. Food and Drug Administration. Potential therapeutic agents for NAFLD include antidiabetic medications, such as pioglitazone, a peroxisome proliferator-activated receptor gamma (PPARc) agonist, and exenatide, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. GLP-1 is derived from the proglucagon molecule. In pancreatic a cells, the proglucagon molecule is processed to glucagon, which increases blood glucose levels. In the gut, GLP-1 and GLP-2 are produced from the same proglucagon molecule. Interestingly, GLP-1 suppresses blood glucose levels by stimulating pancreatic b cells to secrete insulin, which is in contrast to glucagon. Because the mechanism of action of GLP-1 receptor agonists is to stimulate insulin secretion to improve insulin resistance and sensitivity, exenatide has been shown to reverse steatohepatitis and is thus a potential therapeutic agent. The protease dipeptidyl peptide4 has been shown to degrade native GLP-1. Notably, exenatide degrades dipeptidyl peptide-4 to maintain the levels of endogenous GLP-1. Although GLP-1mediated insulin secretion in pancreatic b cells has been well documented, the role of GLP-1 signaling and exenatide’s mechanism of action, which is thought to include the induction of carcinoembryonic antigenAbbreviations: CEACAM1, carcinoembryonic antigen-related cell adhesion molecule 1; FASN, fatty acid synthase; GLP-1, glucagonlike peptide-1; HFD, high-fat diet; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; PPARc, peroxisome proliferator-activated receptor gamma.

hepatology communications

A new mechanism of action of glucagon‐like peptide‐1 agonist in hepatic steatosis: Promotion of hepatic insulin clearance through induction of carcinoembryonic antigen‐related cell adhesion molecule 1